Terms: = Breast cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Treatment
54 results:
1. Tumor-infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer Family Registry.
Ransohoff JD; Miller I; Koo J; Joshi V; Kurian AW; Allison KH; John EM; Telli ML
JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38547391
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative breast cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Martín M; Yoder R; Salgado R; Del Monte-Millán M; Álvarez EL; Echavarría I; Staley JM; O'Dea AP; Nye LE; Stecklein SR; Bueno C; Jerez Y; Cebollero M; Bueno O; García Saenz JÁ; Moreno F; Bohn U; Gómez H; Massarrah T; Khan QJ; Godwin AK; López-Tarruella S; Sharma P
Clin Cancer Res; 2024 May; 30(10):2160-2169. PubMed ID: 38466643
[TBL] [Abstract] [Full Text] [Related]
3. Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
Garcia-Torralba E; Pérez Ramos M; Ivars Rubio A; Navarro Manzano E; Blaya Boluda N; Lloret Gil M; Aller A; de la Morena Barrio P; García Garre E; Martínez Díaz F; García Molina F; Chaves Benito A; García-Martínez E; Ayala de la Peña F
Breast Cancer Res Treat; 2024 Jun; 205(3):475-485. PubMed ID: 38453782
[TBL] [Abstract] [Full Text] [Related]
4. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
5. treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory breast cancer-Treated with Neoadjuvant Systemic Therapy.
De Schepper M; Nguyen HL; Richard F; Rosias L; Lerebours F; Vion R; Clatot F; Berghian A; Maetens M; Leduc S; Isnaldi E; Molinelli C; Lambertini M; Grillo F; Zoppoli G; Dirix L; Punie K; Wildiers H; Smeets A; Nevelsteen I; Neven P; Vincent-Salomon A; Larsimont D; Duhem C; Viens P; Bertucci F; Biganzoli E; Vermeulen P; Floris G; Desmedt C
Cancer Res Commun; 2024 Jan; 4(1):186-199. PubMed ID: 38147006
[TBL] [Abstract] [Full Text] [Related]
6. The clinical efficacy of Apatinib plus Ba Zhen granules in the treatment of advanced unresectable differentiated thyroid cancer and their influence on immune factors.
Bai Y; Jin J; Liu Y; Zhang B; Li J
Pak J Pharm Sci; 2023 May; 36(3(Special)):935-939. PubMed ID: 37587701
[TBL] [Abstract] [Full Text] [Related]
7. Genomics of
Lipsyc-Sharf M; Jain E; Collins LC; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Come SE; Peppercorn JM; Borges VF; Warner E; Snow C; Krop IE; Kim D; Weiss J; Zanudo JGT; Partridge AH; Wagle N; Waks AG
JCO Precis Oncol; 2023 Jun; 7():e2300076. PubMed ID: 37364233
[TBL] [Abstract] [Full Text] [Related]
8. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.
Donnenberg VS; Luketich JD; Sultan I; Lister J; Bartlett DL; Ghosh S; Donnenberg AD
Front Immunol; 2023; 14():1157697. PubMed ID: 37063842
[TBL] [Abstract] [Full Text] [Related]
9. Mendelian Randomization Study on Causal Association of IL-6With breast cancer.
Zhang M; Ma N; Wang R
Clin Breast Cancer; 2023 Jun; 23(4):e182-e188. PubMed ID: 36813657
[TBL] [Abstract] [Full Text] [Related]
10. Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative breast cancer.
Nederlof I; Voorwerk L; Kok M
Clin Cancer Res; 2023 Jul; 29(13):2362-2370. PubMed ID: 36622327
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic yoga reduces pro-tumorigenic cytokines in cancer survivors.
Patel DI; Almeida GJ; Darby NT; Serra MC; Calderon T; Lapetoda A; Gutierrez B; Ramirez AG; Hughes DC
Support Care Cancer; 2022 Dec; 31(1):33. PubMed ID: 36517621
[TBL] [Abstract] [Full Text] [Related]
12. Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Graeser M; Gluz O; Biehl C; Ulbrich-Gebauer D; Christgen M; Palatty J; Kuemmel S; Grischke EM; Augustin D; Braun M; Potenberg J; Wuerstlein R; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Ni H; Kolberg-Liedtke C; Feuerhake F; Kreipe HH; Nitz U; Harbeck N
Clin Cancer Res; 2023 Feb; 29(4):805-814. PubMed ID: 36441798
[TBL] [Abstract] [Full Text] [Related]
13. Establishment and validation of a LC-MS/MS method for the determination of anlotinib in human plasma: Application to therapeutic drug monitoring.
Yu M; Liang Z; Xiong L; Liu F; Cheng L; Jia C; Qi X; Sun F
Biomed Chromatogr; 2022 Dec; 36(12):e5501. PubMed ID: 36082703
[TBL] [Abstract] [Full Text] [Related]
14. The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer.
Ilgun AS; Aktepe F; Gonullu O; Kapucuoglu N; Yararbas K; Alco G; Ozturk A; Elbuken Celebi F; Erdogan Z; Ordu C; Unal C; Duymaz T; Soybir G; Yavuz E; Tuzlali S; Ozmen V
Future Oncol; 2022 Sep; 18(29):3289-3298. PubMed ID: 36017739
[TBL] [Abstract] [Full Text] [Related]
15. "A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring".
Soledad Poetto A; Posocco B; Zanchetta M; Gagno S; Orleni M; Canil G; Alberti M; Puglisi F; Toffoli G
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Sep; 1207():123403. PubMed ID: 35940043
[TBL] [Abstract] [Full Text] [Related]
16. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative breast cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Gluz O; Nitz U; Kolberg-Liedtke C; Prat A; Christgen M; Kuemmel S; Mohammadian MP; Gebauer D; Kates R; Paré L; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Wuerstlein R; Graeser M; Pelz E; Jóźwiak K; Zu Eulenburg C; Kreipe HH; Harbeck N;
Clin Cancer Res; 2022 Nov; 28(22):4995-5003. PubMed ID: 35797219
[TBL] [Abstract] [Full Text] [Related]
17. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of breast cancer Subtypes.
Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
[TBL] [Abstract] [Full Text] [Related]
18. Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy.
Okcu O; Öztürk SD; Öztürk Ç; Şen B; Yasin Aİ; Bedir R
Ann Diagn Pathol; 2022 Jun; 58():151930. PubMed ID: 35245821
[TBL] [Abstract] [Full Text] [Related]
19. Anticancer Potential of silibinin Loaded Polymeric Nanoparticles against breast cancer Cells: Insight into the Apoptotic Genes Targets.
Pourgholi A; Dadashpour M; Mousapour A; Firouzi Amandi A; Zarghami N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2587-2596. PubMed ID: 34452574
[TBL] [Abstract] [Full Text] [Related]
20. Uncovering Barriers to Screening for Distress in Patients With cancer via Machine Learning.
Günther MP; Kirchebner J; Schulze JB; Götz A; von Känel R; Euler S
J Acad Consult Liaison Psychiatry; 2022; 63(2):163-169. PubMed ID: 34438098
[TBL] [Abstract] [Full Text] [Related]
[Next]
